NICE Endorses Rozanolixizumab for Myasthenia Gr...

By João L. Carapinha

May 1, 2026

Rozanolixizumab myasthenia gravis treatment has been recommended by the National Institute for Health and Care Excellence (NICE) as an add-on to standard care for adults with generalised myasthenia gravis (gMG) who are positive for anti-acetylchol...
Accelerating Biotechnology Patient Access in Europe Through Strategic Policy ...
Insulin Substitution Portugal: Implications of Novo Nordisk’s Discontin...
Dementia Pharmacotherapy Guidelines: Emphasizing Non-Pharmacological Approach...
Gaps in AI Governance Healthcare Frameworks: Ensuring Effective Implementatio...
Enhancing Health Technology Assessment Transparency through Digital Innovation
Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometab...
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO ...
Establishing a Vaccine Confidence Strategy: EMA’s New Advisory Group Ta...
Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector
Advancing Subcutaneous Diuretic Therapy for Heart Failure Management
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program f...